Why integrity testing is the unsung hero of the single-use bioprocessing?
Single-use technologies were supposed to make life simpler. No cleaning validation. No cross-contamination risk. Faster changeovers. And for the most part, they delivered — transforming how the biopharmaceutical industry builds and runs its manufacturing processes. But simplicity has a catch: the easier something is to use, the easier it is to overlook what can go wrong.
A single-use assembly is only as good as its weakest seal.
That quiet truth sits at the center of every product transfer, every filtration run, and every filling operation that relies on a custom-assembled single-use system. Integrity — the assurance that a closed system stays closed — is not a nice-to-have. It is the foundation on which every other guarantee in biopharmaceutical manufacturing rests.
The complexity hidden inside a simple bag
Modern single-use assemblies are deceptively sophisticated. Behind what looks like a collection of bags, tubing, and connectors sits an engineered system with dozens of potential failure points — filter interfaces, weld seams, aseptic connectors, luer connections. Each junction is a potential leak. Each interface under pressure is a test waiting to happen.
At Biotecha, every custom assembly is designed around a specific bioprocessing workflow. That precision is the point. But every unique configuration must be verified — you cannot rely on a catalogue certificate when the assembly is bespoke. Integrity testing is not a regulatory checkbox. It is the last line of defense before a potential contamination event.
The 10 µm question
Our integrity testing method development targets defects equivalent to a 10 µm nominal diameter orifice — roughly one-tenth the width of a human hair. Invisible to the naked eye, yet a credible pathway for microbial ingress into a sterile fluid path.
The method is pressure-based: a closed assembly is pressurized, stabilized, and monitored for decay. Any measurable loss signals a breach. The test is non-destructive, deterministic, and designed to answer the integrity question before a single milliliter of product is at risk.
That distinction matters. Probabilistic approaches — visual inspection, sampling — offer confidence bounded by human perception. A pressure test gives a direct, physical result: it holds, or it doesn't.
As single-use technologies push further into gene therapy, cell therapy, and high-value biologics, the cost of contamination event only grows. In that environment, integrity isn't a feature. It's the product.
By BIOTECHA Single-Use Assembly Development Team
Bron: INTO Bioprocess Solutions